Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

AZ pays $240mm up front for mRNA collaboration with Moderna

10 Aug 2016

Executive Summary

Marking the largest up-front for a non-marketed product so far this year, AstraZeneca PLC has paid Moderna Therapeutics Inc. (messenger RNA therapeutic development for various diseases) $240mm for options to develop and sell up to 40 new cardiometabolic, renal, and cancer compounds based on Moderna’s messenger RNA Therapeutics technology.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By